Clinical Trials Search
Clinical Trial 18395
Interventions:G100; Pembrolizumab (Keytruda)
Study Type: Treatment
Phase of Study: Phase I/II
- Bela Kis
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma
In this trial, the safety, immunogenicity, and clinical efficacy of G100 will be examined alone or with pembrolizumab.
Primary: To evaluate the safety and tolerability of ascending doses of intratumoral G100 in patients with follicular non-Hodgkin's lymphoma (NHL) receiving local radiation. Secondary: To assess clinical responses by Immune-related Response Criteria (irRC) using bi-dimensional measurements and time to progression (TTP) as a preliminary indication of efficacy. To assess abscopal tumor responses in non-treated, distal tumor sites. To evaluate pre- and post-regimen tumor tissue and blood for exploratory biomarkers of immunologic and tumor response.